纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | ITPK1 |
Uniprot No | Q13572 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-414aa |
氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMQTFLK GKRVGYWLSE KKIKKLNFQA FAELCRKRGM EVVQLNLSRP IEEQGPLDVI IHKLTDVILE ADQNDSQSLE LVHRFQEYID AHPETIVLDP LPAIRTLLDR SKSYELIRKI EAYMEDDRIC SPPFMELTSL CGDDTMRLLE KNGLTFPFIC KTRVAHGTNS HEMAIVFNQE GLNAIQPPCV VQNFINHNAV LYKVFVVGES YTVVQRPSLK NFSAGTSDRE SIFFNSHNVS KPESSSVLTE LDKIEGVFER PSDEVIRELS RALRQALGVS LFGIDIIINN QTGQHAVIDI NAFPGYEGVS EFFTDLLNHI ATVLQGQSTA MAATGDVALL RHSKLLAEPA GGLVGERTCS ASPGCCGSMM GQDAPWKAEA DAGGTAKLPH QRLGCNAGVS PSFQQHCVAS LATKASSQ |
预测分子量 | 48 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ITPK1重组蛋白的模拟参考文献示例(供参考,具体文献需根据实际研究查询):
---
1. **标题**:*Recombinant Human ITPK1: Expression, Purification, and Kinetic Analysis*
**作者**:Wilson, J. et al. (2020)
**摘要**:本研究成功在大肠杆菌中表达并纯化了重组人源ITPK1蛋白,通过体外激酶实验揭示了其对肌醇磷酸底物的特异性催化活性,为后续药物筛选提供了工具。
2. **标题**:*Crystal Structure of ITPK1 Reveals Substrate Recognition Mechanism*
**作者**:Chakraborty, S. et al. (2019)
**摘要**:利用重组ITPK1蛋白的晶体结构解析,阐明了其与肌醇三磷酸(IP3)的结合模式及催化位点的关键氨基酸残基,揭示了其磷酸化调控的分子基础。
3. **标题**:*ITPK1 Recombinant Protein Modulates Immune Response in Macrophages*
**作者**:Smith, L. et al. (2021)
**摘要**:通过体外实验证明,重组ITPK1蛋白通过调控IP6代谢通路影响巨噬细胞的炎症因子分泌,提示其在先天免疫中的潜在作用。
4. **标题**:*Functional Characterization of Rice ITPK1 Recombinant Protein in Phytic Acid Biosynthesis*
**作者**:Zhou, Y. et al. (2018)
**摘要**:克隆并表达了水稻ITPK1重组蛋白,验证其在植物植酸合成途径中的关键催化功能,为作物营养改良提供理论依据。
---
**注意**:以上文献为示例,实际研究中需通过学术数据库(如PubMed、Web of Science)检索真实发表的论文。如需具体文献,可提供更详细的研究方向或关键词进一步筛选。
ITPK1 (Inositol 1.3.4-Triphosphate 5/6-Kinase 1) is a key enzyme in inositol phosphate metabolism, primarily involved in phosphorylating inositol 1.3.4-triphosphate (Ins(1.3.4)P3) to produce higher phosphorylated inositol derivatives, such as inositol 1.3.4.5-tetrakisphosphate (Ins(1.3.4.5)P4) and inositol 1.3.4.5.6-pentakisphosphate (InsP5). These metabolites play critical roles in cellular signaling, including calcium regulation, gene expression, and cellular stress responses. ITPK1’s activity influences diverse physiological processes, such as immune function, neuronal development, and energy metabolism, making it a focal point in studying diseases like cancer, neurodegenerative disorders, and inflammatory conditions.
Recombinant ITPK1 protein is engineered using expression systems like *E. coli* or mammalian cells to ensure proper folding and post-translational modifications. Purification techniques, such as affinity chromatography with His-tags or GST-tags, yield high-purity protein for functional studies. Researchers utilize recombinant ITPK1 to dissect its enzymatic mechanisms, substrate specificity, and interactions with regulatory proteins. Its role in modulating inositol pyrophosphates (e.g., InsP7/InsP8), which regulate cellular processes like vesicle trafficking and apoptosis, underscores its therapeutic potential.
In drug discovery, recombinant ITPK1 serves as a tool to screen small-molecule inhibitors or activators targeting inositol phosphate pathways. Dysregulation of ITPK1 has been linked to pathologies, including glioblastoma and metabolic syndromes, positioning it as a biomarker or therapeutic target. Structural studies using recombinant protein have revealed conformational changes during catalysis, aiding in rational drug design. Overall, ITPK1 recombinant protein bridges basic research and translational applications, offering insights into cellular signaling networks and opportunities for novel therapeutics.
×